Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antiarrhythmic/cefalàlgia
L'enllaç es desa al porta-retalls
Pàgina 1 des de 55 resultats
Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Dofetilide is a new antiarrhythmic agent recently approved for the conversion of and maintenance of sinus rhythm in patients with atrial fibrillation (AF) and atrial flutter (AFl). Dofetilide is a selective class III antiarrhythmic drug which works by selectively blocking the rapid component of the
Sotalol: a new class III antiarrhythmic agent.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of sotalol hydrochloride are reviewed. The chemical name of sotalol hydrochloride is 4'-[1-hydroxy-2-(isopropylamino)ethyl]methanesulfonanilide monohydrochloride. Sotalol is a class III antiarrhythmic that
Intravenous lidocaine and mexiletine in the management of trigeminal autonomic cephalalgias.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Lidocaine and mexiletine are class 1B antiarrhythmic drugs that act on sodium channels. Lidocaine is also an important anesthetic and topical agent that is useful in the treatment of multiple pain disorders, and mexiletine is commonly used for neuropathic pain and myotonia. Both intravenous
Moricizine: a new class I antiarrhythmic.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of the Class I antiarrhythmic agent moricizine hydrochloride are reviewed. Moricizine is chemically similar to the phenothiazines but does not appear to block dopaminergic receptors. Its major
[Clinical study of the antiarrhythmic action of Mexityl in ventricular disorders of the cardiac rhythm].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The anti-arrhythmic activity of mexitil was studied in 36 patients with frequent, prognostically unfavourable ventricular extrasystoles of various etiology. Quantitative and qualitative assessment of rhythm disorders was accomplished by bicycle ergometry and ECG recording for 24 hours by means of
Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Twenty-eight subjects underwent evaluation of drug toxicity and antiarrhythmic efficacy with oral and intravenous lorcainide. Lorcainide, a new type 1C antiarrhythmic drug, has an active metabolite, norlorcainide, which accumulates after oral but not significantly after intravenous administration.
Long-term antiarrhythmic therapy with flecainide.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The antiarrhythmic efficacy and safety of oral flecainide were assessed during a controlled 2-week and a subsequent 48-week long-term trial. Fifteen patients with frequent (more than 30 per hour) and complex ventricular arrhythmias (Lown grade IVA or IVB) who had been resistant or intolerant to 2 or
Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The chemistry, electrophysiology, pharmacokinetics, clinical use and efficacy, adverse effects, drug interactions, and dosage of encainide hydrochloride and flecainide acetate are reviewed. Encainide and flecainide are class 1c antiarrhythmic agents that slow myocardial conduction and mildly prolong
Antiarrhythmic efficacy and tolerance of oral propafenone in patients with frequent ventricular arrhythmias: experience of a multicentre study.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
In a multicentre study efficacy and safety of propafenone 450 mg day-1 and 750 mg day-1 was studied in 97 patients with frequent ventricular premature beats (VPB greater than 30 h-1). 70 patients suffered from organic heart disease, in 27 patients no organic heart disease was present during an
[Anti-arrhythmia effect of prolecophen in patients with extrasystole in comparison with other anti-arrhythmia drugs].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Oral prolecohen (LEK, Yugoslavia) was given in a single dose of 300 mg to 15 patients with extrasystole of various genesis. The drug produced an antiarrhythmic effect in 50% of patients with ventricular extrasystole, but in those with supraventricular extrasystole. Prolecophenum showed a good
Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
In a clinical trial the efficacy of encainide, a newly developed class I antiarrhythmic agent, was compared with the well-known mexiletine. Nine patients with different underlying cardiac disease and chronic complex ventricular ectopies (documented by 24-h Holter monitoring, confirmed during the
Encainide: a new antiarrhythmic agent.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Encainide is classified as a type Ic antiarrhythmic agent. Absorption is essentially complete, but bioavailability is variable because of first-pass metabolism. Two metabolic phenotypes, extensive and poor metabolizers, have been identified. O-demethyl encainide and 3-methoxy-O-demethyl encainide
[Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Disopyramide (B 712) was tested in 39 patients with chronic arrhythmias of different kind: 23 cases with atrial fibrillation, 16 cases with ventricular ectopic beats, two cases with supraventricular tachycardias. The effect of disopyramide was compared to a pretreatment with one or several
Azimilide, a novel oral class III antiarrhythmic for both supraventricular and ventricular arrhythmias.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Azimilide is an investigational Class III antiarrhythmic that has been developed for treating both supraventricular and ventricular tachyarrhythmias. Similar to other Class III antiarrhythmics, azimilide prolongs myocardial repolarization in a dose-dependent manner by increasing the action potential
The antiarrhythmic properties of quifenadine, H1-histamine receptor blocker in children with premature beats: a randomized controlled pilot trial.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Despite evolving success of mini-invasive techniques in treating cardiac arrhythmias in children, pharmaceuticals remain the cornerstone therapeutic option. Beyond conventional antiarrhythmic agents such as amiodarone, local anesthetics, tranquilizers, anticonvulsants, and neuroleptics exhibit
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
